FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease
…, DA Lomas, A Ludwig-Sengpiel… - American journal of …, 2017 - atsjournals.org
Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting
β 2 -agonist (LABA) therapy in patients with chronic obstructive pulmonary …
β 2 -agonist (LABA) therapy in patients with chronic obstructive pulmonary …
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled …
…, K Forster, M Rolke, A Ludwig-Sengpiel… - The Lancet …, 2022 - thelancet.com
Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …
SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects
O Holz, S Khalilieh, A Ludwig-Sengpiel… - European …, 2010 - Eur Respiratory Soc
SCH527123 is a novel, selective CXC chemokine receptor 2 antagonist that inhibits neutrophil
activation and modulates neutrophil trafficking in animal models, characteristics that may …
activation and modulates neutrophil trafficking in animal models, characteristics that may …
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
…, A Linnhoff, A Ludwig-Sengpiel… - The Lancet …, 2023 - thelancet.com
Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin. The drug has been tested previously in the phase 3 NAVIGATOR (NCT03347279) …
lymphopoietin. The drug has been tested previously in the phase 3 NAVIGATOR (NCT03347279) …
[HTML][HTML] A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients
…, RA Wise, A Ludwig-Sengpiel… - European …, 2021 - Eur Respiratory Soc
Suboptimal adherence to maintenance therapy contributes to poor asthma control and
exacerbations. This study evaluated the effect of different elements of a connected inhaler system …
exacerbations. This study evaluated the effect of different elements of a connected inhaler system …
Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre …
…, G Illies, A Eich, A Ludwig-Sengpiel… - The Lancet …, 2022 - thelancet.com
Background Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are
associated with changes in the sputum microbiome, including an increased prevalence of …
associated with changes in the sputum microbiome, including an increased prevalence of …
A new class of bronchodilator improves lung function in COPD: a trial with GSK961081
PLML Wielders, A Ludwig-Sengpiel… - European …, 2013 - Eur Respiratory Soc
GSK961081 is a bifunctional molecule demonstrating both muscarinic antagonist and β-agonist
activities. This was a 4-week, multicentre, randomised, double-blind, double-dummy, …
activities. This was a 4-week, multicentre, randomised, double-blind, double-dummy, …
A multicentre, randomized, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability, and pharmacokinetics of repeat doses of …
…, J Robertson, JN Hamblin, A Ludwig-Sengpiel… - … of Pharmacology and …, 2018 - ASPET
Phosphoinositide 3-kinase δ (PI3Kδ) is a lipid kinase involved in leukocyte recruitment and
activation. Activation of PI3Kδ has been linked to airway inflammation and asthma …
activation. Activation of PI3Kδ has been linked to airway inflammation and asthma …
[HTML][HTML] Baseline characteristics from a 3-year longitudinal study to phenotype subjects with COPD: the FOOTPRINTS study
…, RM Mroz, W Janssens, A Ludwig-Sengpiel… - Respiratory …, 2023 - Springer
Background FOOTPRINTS ® is a prospective, longitudinal, 3-year study assessing the
association between biomarkers of inflammation/lung tissue destruction and chronic obstructive …
association between biomarkers of inflammation/lung tissue destruction and chronic obstructive …
TRONARTO: a randomized, placebo-controlled study of tiotropium/olodaterol delivered via soft mist inhaler in COPD patients stratified by peak inspiratory flow
DA Mahler, A Ludwig-Sengpiel… - … Journal of Chronic …, 2021 - Taylor & Francis
Background Inhaled bronchodilator therapy is currently the mainstay of treatment for patients
with chronic obstructive pulmonary disease (COPD). Some inhalers require patients to …
with chronic obstructive pulmonary disease (COPD). Some inhalers require patients to …